Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Liora M. Schultz

Consulting or Advisory Role: Novartis

Jenna Rossoff

Consulting or Advisory Role: Novartis

Christa Krupski

Employment: US Acute Care Solutions (I)

Stock and Other Ownership Interests: US Acute Care Solutions (I)

Travel, Accommodations, Expenses: US Acute Care Solutions (I)

Christine L. Phillips

Consulting or Advisory Role: Novartis, Incyte

Julie-An Talano

Consulting or Advisory Role: Novartis

Susanne H.C. Baumeister

Employment: Takeda (I)

Stock and Other Ownership Interests: Takeda (I), AstraZeneca (I)

Gary Douglas Myers

Honoraria: Novartis

Consulting or Advisory Role: Novartis

Speakers' Bureau: Novartis

Research Funding: Novartis (Inst)

Patrick A. Brown

Consulting or Advisory Role: Novartis, Jazz Pharmaceuticals, Servier, Kite, a Gilead Company, Amgen, Kura Oncology, Takeda

Muna Qayed

Honoraria: Novartis, Vertex

Consulting or Advisory Role: Novartis

Travel, Accommodations, Expenses: Novartis

Michelle Hermiston

Stock and Other Ownership Interests: Gladiator Biosciences (I), Coagulant Therapeutics (I)

Consulting or Advisory Role: Novartis, Sobi, KaliVir Immunotherapeutics (I)

Patents, Royalties, Other Intellectual Property: Spouse has patents pending for platform technology with application to oncology, diagnostics, and anti-infections and for antibleeding technology (I)

Prakash Satwani

Consulting or Advisory Role: Takeda

Speakers' Bureau: SOBI

Open Payments Link: https://openpaymentsdata.cms.gov/physician/1047592

Rachel Wilcox

Research Funding: Novartis (Inst), AlloVir (Inst)

Travel, Accommodations, Expenses: Novartis

Vanessa A. Fabrizio

Consulting or Advisory Role: Adaptimmune

Crystal L. Mackall

Leadership: Syncopation Life Sciences

Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Biopharma, Apricity Health, Syncopation Life Sciences, Ensoma, Mammoth Biosciences

Consulting or Advisory Role: Vor Biopharma, Apricity Health, Alimera Sciences, PACT Pharma, Nektar, Lyell Immunopharma, NeoImmuneTech, Syncopation Life Sciences, NeoImmuneTech, Bristol Myers Squibb, Immatics, GlaxoSmithKline, Ensoma, Mammoth Biosciences

Research Funding: Lyell Immunopharma

Patents, Royalties, Other Intellectual Property: I am an inventor on numerous patents related to chimeric antigen receptor therapeutics and received royalties from NIH for the CD22-CAR patent licensed to Juno therapeutics

Travel, Accommodations, Expenses: NeoImmuneTech, Roche, Nektar

Other Relationship: Lyell Immunopharma, Syncopation Life Sciences

Kevin J. Curran

Honoraria: Novartis

Consulting or Advisory Role: Novartis, Mesoblast

Research Funding: Juno Therapeutics, Celgene (Inst), Novartis (Inst), Cellectis (Inst)

Michael R. Verneris

Stock and Other Ownership Interests: Fate Therapeutics

Honoraria: Novartis, Jazz Pharmaceuticals

Patents, Royalties, Other Intellectual Property: patent to make innate lymphoid cells. It is not licensed, patent for CAR T-cell homing

Theodore W. Laetsch

Stock and Other Ownership Interests: Advanced Microbubbles

Consulting or Advisory Role: Novartis, Bayer, Cellectis, Aptitude Health, Clinical Education Alliance, Deciphera, Jumo Health, Massive Bio, Med Learning Group, Medscape, Physicians' Education Resource, Y-mAbs Therapeutics, AI Therapeutics, Jazz Pharmaceuticals, GentiBio, Menarini, Pyramid Biosciences

Research Funding: Pfizer (Inst), Novartis (Inst), Bayer (Inst), AbbVie (Inst), Amgen (Inst), Atara Biotherapeutics (Inst), Bristol Myers Squibb (Inst), Lilly (Inst), Epizyme (Inst), GlaxoSmithKline (Inst), Janssen (Inst), Jubilant Pharmaceuticals (Inst), Novella Clinical (Inst), Servier (Inst), Foundation Medicine (Inst), Merck Sharp & Dohme (Inst), Turning Point Therapeutics (Inst)

Heather Stefanski

Honoraria: Novartis

No other potential conflicts of interest were reported.